ChapsVision Strengthens AI Capabilities with Sinequa Acquisition and Completes New US$90M Funding Round. Learn more

Chat with Sinequa Assistant
Sinequa GenAI AssistantSinequa GenAI Assistant

Informing Pharma Research

Business issues

This global biopharmaceutical company focuses on neurological and immunological diseases including Epilepsy, Parkinson’s Disease and Rheumat oid Arthritis. In labs and offices ar ound the world, 7,643 employees work to develop both new chemical entities and biological entities in an effort to improve the lives of people suffering from these devastating diseases.

Challenge

Expertise and data were scattered around the world. The company needed a solution to make expertise and information widely available. The effort to build effective search-based applications started over ten years ago, but the previously use products didn’t have the depth of capabilities needed to support the company’s deep search-based application needs.

Like its peers, this pharmaceutical company faces a multi-year process to bring a drug to market and achieve global availability, and at every step, efficacy and regulatory hurdles must be traversed. Before a clinical trial is even approved, the company must first demonstrate that there is no global evidence that the same, or similar molecule, has done harm to humans. Efficacy comes next.

Information and insights are gained at each juncture that are critical to team members throughout this 12-30 year process to bring a drug to market. Painstaking futile search adds time, risk and cost to this already long process.

Pharma R&D

Solution

Implement an enterprise-level information-driven development platform that contextualizes information to inform decisions, improve productivity and innovation that reduce risk, lower costs and enable faster time-to-market of new drugs.

Pre-clinical, Phase 1 and 2 drug test risk monitoring for earlier identification of problems to create more accurate end-point achiements and improve the pass/fail ratio.

Proactively mitigate compliance risk by answering regulator’s questions quickly and completely.

All the legacy data, all the piles of research we produced 10-15-20 years ago where it’s still beneficial whenever you have a new project to go back to what was done. That’s what we’re talking about with Sinequa. To go and have a very quick search into the past, into the corporate memory.

IT Manager

Annualized Results

The Sinequa solution included identifying and quantifying the benefit of solving life science specific business issues. The following results include the corresponding annual benefit:

  • Identify Pre-clinical, Phase 1 and 2 risks, improve the pass/fail ratio, decreasing time-to-market | €126M / $143M
  • Increased efficiency of 1,500 clinicians | €3.48M / $3.95M
  • Increase efficiency of 3,750 non-clinicians | €2.1M / $2.4M
  • Decrease the cost compliance and regulatory risk
It could be something like €300,000-400,000 a day (the value of bringing a drug to market sooner.)

Senior Project Manager, Global IT Drug Development